Gentis news

                        Array
(
    [0] => stdClass Object
        (
            [id] => 1417
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 800x600-web-1.png
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2026-03-19
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-03-19 08:42:43
            [updated_time] => 2026-03-24 15:16:17
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-will-present-at-the-workshop-advances-in-reproductive-medicine-13
            [title] => Eurofins GENTIS will present at the workshop “Advances in Reproductive Medicine 13”
            [description] => On March 28, 2026, at Melia Hanoi Hotel, the Hanoi Society for Reproductive Support will organize the scientific workshop “Advances in Reproductive Medicine 13” with the theme: “How to improve IVF cycle success rates.” This is one of the most important annual academic events in the field of reproductive support in Vietnam, attracting significant attention from doctors, scientists, embryologists, and healthcare managers in reproductive medicine.
            [content] => 
In the context of the increasing demand for infertility treatment, along with the rapid development of biotechnology and genetics, updating scientific advances and sharing practical experience in IVF (in vitro fertilization) treatment has become especially essential. The workshop “Advances in Reproductive Medicine 13” is organized to create a prestigious scientific forum where leading experts can discuss new trends, current challenges, and solutions to improve treatment outcomes in reproductive support.

An academic forum gathering leading experts in reproductive support
 According to the agenda, the workshop will include 4 in-depth scientific sessions focusing on key topics in current reproductive practice, including:
- Ovarian stimulation
- Genetics and new technologies in reproductive support
- Quality management in reproductive support
- Risk management and quality improvement
The discussion sessions are designed to provide a comprehensive perspective on factors affecting IVF success rates, from clinical strategies and advanced testing technologies to quality management systems and risk control in laboratories and reproductive centers.
In particular, the second session, themed “Genetics and new technologies in reproductive support,” is expected to deliver updated insights into the role of genetic testing techniques, sequencing technologies, and genetic applications in improving infertility treatment outcomes.
PhD Pham Dinh Minh to present on gene testing applications in IVF
 At Session 2: “Genetics and new technologies in reproductive support,” PhD Pham Dinh Minh – R&D Director of Eurofins GENTIS will present a report titled: “Enhancing IVF efficiency and success rates through gene testing and genetics.” The presentation will take place from 10:15 to 12:00 on March 28, 2026, at Melia Hanoi Hotel.
In recent years, gene testing techniques and genetic analysis have become an essential part of reproductive medicine. Advances in next-generation sequencing (NGS) and modern genetic analysis methods allow early detection of genetic abnormalities, enabling clinicians to make more precise treatment decisions.

The application of genetic testing in IVF can bring several benefits such as:
- Screening for chromosomal abnormalities in embryos
- Detecting hereditary diseases that may be passed to future generations
- Optimizing embryo selection for transfer
- Improving implantation potential and pregnancy success rates
Through this presentation, PhD Pham Dinh Minh will share the latest updates on genetic testing technologies in reproductive support and analyze how these methods can contribute to improving IVF treatment outcomes in clinical practice.
An experienced expert in genetics and omics sciences
 PhD Pham Dinh Minh is a scientist with many years of experience in Biochemistry, Omics sciences, Genetics, and medical testing. With over 10 years of experience in teaching and research, he has participated in numerous domestic and international scientific projects, making significant contributions to the development of biotechnology applications in medicine.
In terms of scientific publications, Dr. Minh is the author and co-author of more than 45 scientific papers, including over 23 articles published in international journals. His research focuses on applications of nanobiotechnology, genome analysis, and innovative technological solutions for disease diagnosis and treatment.
Additionally, Dr. Minh is the lead author of one book chapter and co-author of another chapter in a monograph on nanobiotechnology published by Wiley in 2023—one of the world’s most reputable scientific publishers.
In research activities, he is currently the principal investigator of one national-level project funded by Nafosted and two projects under the Ministry of Science and Technology related to nanobiotechnology and stem cells. He also serves as a key member in two international collaborative projects and two national-level projects.
Beyond research, Dr. Minh is actively involved in scientific training. He has supervised 1 PhD candidate, 5 master’s students, and 6 bachelor’s students, contributing to the development of the next generation of scientists in biotechnology and genetics.
Opportunities for knowledge update and professional networking
 The workshop “Advances in Reproductive Medicine 13” is expected to provide valuable scientific insights, helping doctors and specialists stay updated with the latest trends in reproductive medicine.
The participation of leading experts and in-depth presentations will create opportunities for delegates to exchange experiences, discuss clinical challenges, and explore solutions to improve IVF success rates.
For doctors, embryologists, and researchers in reproductive medicine, this is also an important occasion for professional networking, sharing practical experience, and accessing new technologies in infertility diagnosis and treatment.
With its highly practical theme and numerous specialized reports, the workshop promises to contribute to the development of reproductive support in Vietnam and open new approaches to enhance treatment effectiveness for patients.
We look forward to welcoming doctors and experts at the workshop “Advances in Reproductive Medicine 13” and encourage you not to miss the presentation by PhD Pham Dinh Minh on the application of gene testing and genetics in improving IVF outcomes.
            [content_more] => 
            [meta_title] => Eurofins GENTIS will present at the workshop “Advances in Reproductive Medicine 13”
            [meta_description] => On March 28, 2026, at Melia Hanoi Hotel, the Hanoi Society for Reproductive Support will organize the scientific workshop “Advances in Reproductive Medicine 13” with the theme: “How to improve IVF cycle success rates.” This is one of the most important an
            [meta_keyword] => Gentis,Hasar
            [thumbnail_alt] => 
            [post_id] => 1417
            [category_id] => 14
        )

    [1] => stdClass Object
        (
            [id] => 1415
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 800x600-web.png
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2026-03-13
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-03-13 14:02:45
            [updated_time] => 2026-03-13 14:06:08
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-launches-PGT-FAST-Embryo-genetic-screening-solution-with-outstanding-turnaround-time
            [title] => Eurofins GENTIS launches PGT-FAST – Embryo genetic screening solution with outstanding turnaround time
            [description] => In recent years, advancements in assisted reproductive technologies have provided the opportunity for millions of couples worldwide to become parents. However, beyond creating embryos through in vitro fertilization (IVF), selecting embryos with good genetic quality remains a crucial factor in achieving successful pregnancies. Numerous studies have shown that chromosomal abnormalities in embryos are among the common causes of implantation failure, early miscarriage, or genetic syndromes in children after birth. Therefore, preimplantation genetic testing (PGT) has become increasingly important in modern IVF procedures. To support fertility centers in optimizing embryo selection, Eurofins GENTIS has launched a new test, PGT-FAST – an embryo genetic screening solution with the outstanding advantage of delivering results in just 15 hours.
            [content] => 

Comprehensive Chromosome Analysis for Embryo Genetic Screening
 PGT-FAST is a preimplantation genetic test performed before embryo transfer during IVF. By analyzing embryonic cells, the test evaluates the chromosomal status of embryos and detects abnormalities that may affect pregnancy development. The test allows for the analysis of all 24 chromosomes in the embryo, identifying numerical chromosomal abnormalities, also known as aneuploidy. These abnormalities can lead to serious genetic syndromes or prevent normal embryo development.
In addition, PGT-FAST can detect large structural chromosomal abnormalities, such as deletions or duplications of 5Mb or larger. These abnormalities may be associated with genetic syndromes that impact the health and development of the child. Embryo genetic screening provides fertility specialists with scientific evidence to select embryos with normal chromosomal complements, thereby increasing implantation rates and improving IVF treatment outcomes.
Significantly Reduced Turnaround Time
 One of the most notable features of PGT-FAST is its ability to significantly shorten analysis and reporting time. The optimized process allows results to be delivered within 15 hours from sample analysis. Rapid turnaround time offers practical benefits for both fertility centers and patients. Physicians can access embryo genetic results more quickly, enabling timely and appropriate clinical decisions during treatment. For many couples undergoing IVF, a shorter waiting period also helps reduce psychological stress and provides greater control over their treatment plan.
Application of Next-Generation Sequencing Technology
 PGT-FAST is based on Next Generation Sequencing (NGS), one of the most advanced and accurate genetic analysis technologies available today. The sequencing system used in this test is based on the Illumina platform (USA), combined with specialized genetic data analysis software, enabling highly accurate detection of abnormalities. The test achieves high sensitivity and specificity, ensuring reliable results for embryo genetic analysis. Utilizing modern analytical technologies not only improves test accuracy but also optimizes processes and reduces turnaround time.
The introduction of PGT-FAST represents another step forward in expanding Eurofins GENTIS’ genetic testing ecosystem in the field of assisted reproduction. This new testing solution is expected to provide fast, accurate, and efficient options for IVF centers and families seeking the opportunity to welcome healthy babies.
In an era where reproductive medicine increasingly emphasizes genetic factors, the development of advanced testing solutions like PGT-FAST is expected to further enhance treatment quality and help families move closer to their dream of becoming parents.
            [content_more] => 
            [meta_title] => Eurofins GENTIS launches PGT-FAST – Embryo genetic screening solution with outstanding turnaround ti
            [meta_description] => To support fertility centers in optimizing embryo selection, Eurofins GENTIS has launched a new test, PGT-FAST – an embryo genetic screening solution with the outstanding advantage of delivering results in just 15 hours.
            [meta_keyword] => GENTIS,PGT-FAST
            [thumbnail_alt] => 
            [post_id] => 1415
            [category_id] => 14
        )

    [2] => stdClass Object
        (
            [id] => 1414
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => z7616146207741_e7cffc3f616d1b8d7390f14ae1bddc50.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2026-03-13
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-03-13 13:33:19
            [updated_time] => 2026-03-13 16:35:38
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-updates-PGT-FAST-and-GEN28-tests-at-Hanoi-General-Hospital-IVF-center
            [title] => Eurofins GENTIS updates PGT-FAST and GEN28 tests at Hanoi General Hospital IVF center
            [description] => Recently, a delegation of experts from Eurofins GENTIS, led by Dr. Nguyen Quang Vinh (Director of Eurofins GENTIS Testing Center), held a professional working session with the doctors and nurses of the Hanoi General Hospital Assisted Reproduction Center. This collaboration aims to update the latest advances in genetic testing, thereby contributing to improved treatment outcomes for families facing infertility. The session also opened opportunities for academic exchange and laid the groundwork for deeper cooperation between the two units in the future.
            [content] => 
The Eurofins GENTIS delegation was welcomed by MSc. MD. Nguyen Duy Phuong – Director of the Assisted Reproduction and Gender Medicine Center, along with doctors, nurses, and technicians from the hospital.

During the session, Pharmacist Duong Thi Phuong (Product Management Specialist at Eurofins GENTIS) presented an overview of PGT-FAST, the most advanced pre-implantation genetic screening test currently developed by Eurofins GENTIS. PGT-FAST is a pre-implantation genetic test performed before embryo transfer in the IVF process, helping assisted reproduction centers select embryos with high genetic quality. The test analyzes embryonic cells to assess genetic status and surveys all 24 chromosomes to detect chromosomal abnormalities (aneuploidy) – a common cause of implantation failure, early miscarriage, or genetic syndromes in newborns.
In addition, PGT-FAST can detect large structural chromosomal abnormalities such as deletions or duplications of 5Mb or more. The test is implemented using next-generation sequencing (NGS) technology on the Illumina platform, combined with advanced genetic data analysis software, ensuring high sensitivity, specificity, and accuracy in embryo genetic analysis.
A notable advantage of PGT-FAST is its rapid turnaround time, taking only about 15 hours from sample analysis to result. This allows doctors to access embryo genetic results quickly and make timely clinical decisions during the IVF cycle.
Alongside PGT-FAST, Pharmacist Phuong also introduced GEN28, a screening service for carriers of common genetic diseases. GEN28 screens 28 severe recessive genetic disease genes, detecting carriers even if they are completely healthy. The test uses NGS technology combined with advanced bioinformatics analysis to identify gene variants that may be passed to the next generation. With only 2–3 ml of whole blood, GEN28 can screen 28 genes associated with 25 genetic diseases and syndromes, including Thalassemia, G6PD deficiency, cystic fibrosis, Tay–Sachs disease, Wilson disease, galactose metabolism disorders, and more. These conditions can have serious, long-term impacts on health and quality of life.

Information on PGT-FAST and GEN28 received great attention from the medical team at Hanoi General Hospital IVF Center. Dr. Nguyen Quang Vinh directly answered many professional questions from the doctors. Additionally, Dr. Vinh emphasized Eurofins GENTIS’s commitment to continue applying advanced testing technologies and strengthening collaboration with assisted reproduction centers to improve patient service quality. At the conclusion of the session, MSc. MD. Nguyen Duy Phuong praised the expert team’s professional sharing and expressed the hope that both parties will continue to enhance cooperation in the future to provide more effective reproductive solutions for patients.
The session ended in an open and collaborative atmosphere. This event reaffirms Eurofins GENTIS’s commitment to delivering modern, accurate, and effective genetic testing solutions, contributing to increased opportunities for many Vietnamese families to become parents.

            [content_more] => 
            [meta_title] => Eurofins GENTIS updates PGT-FAST and GEN28 tests at Hanoi General Hospital IVF center
            [meta_description] => center
Recently, a delegation of experts from Eurofins GENTIS, led by Dr. Nguyen Quang Vinh (Director of Eurofins GENTIS Testing Center), held a professional working session with the doctors and nurses of the Hanoi General Hospital Assisted Reproduction 
            [meta_keyword] => GENTIS,PGT-FAST,GEN28
            [thumbnail_alt] => 
            [post_id] => 1414
            [category_id] => 14
        )

    [3] => stdClass Object
        (
            [id] => 1408
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => c297db27af2f2171783e.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2026-02-06
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-02-06 09:54:55
            [updated_time] => 2026-02-27 13:51:10
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Summary-of-5-hereditary-cancer-testing-packages-at-Eurofins-GENTIS
            [title] => Summary of 5 hereditary cancer testing packages at Eurofins GENTIS
            [description] => Cancer is one of the leading causes of death worldwide. Numerous studies indicate that 5–10% of cancer cases are associated with hereditary factors, resulting from gene mutations that can be passed down from one generation to the next. Hereditary cancer testing helps identify risks early, enabling the development of appropriate monitoring, prevention, and medical intervention strategies.
            [content] => 
Understanding the growing demand for genetic screening in the community, Eurofins GENTIS has developed five hereditary cancer testing packages ranging from basic to advanced levels, tailored to different individuals, age groups, and family histories.
Why consider hereditary cancer testing?
Unlike conventional tests that detect cancer after it develops, hereditary cancer testing focuses on genetic analysis to determine cancer risk before clinical symptoms appear.
Key benefits include:

Early detection of potential hereditary cancer risks
Proactive development of personalized screening plans
Support for physicians in prevention and treatment counseling
Provision of valuable genetic information for family members
Reduced psychological burden through better understanding of personal health risks


With internationally standardized laboratories and an experienced team of genetic experts, Eurofins GENTIS delivers accurate, reliable testing solutions tailored to the Vietnamese population.

Summary of 5 hereditary cancer testing packages at Eurofins GENTIS
LADY - CARE: Hereditary cancer testing package for women
LADY - CARE is specifically designed for women, focusing on cancers with high incidence rates and strong hereditary associations.

Analysis of 10 genes
Screening for hereditary breast cancer, ovarian cancer, and colorectal cancer


Suitable for:

Women with a family history of breast, ovarian, or colorectal cancer
Women who wish to proactively assess hereditary cancer risk
Women of reproductive or middle age


LADY - CARE helps women better understand their genetic risks and develop appropriate medical monitoring and intervention plans to enhance quality of life.

MEN - CARE: Hereditary cancer screening solution for Men
Men also face various cancers influenced by hereditary factors, particularly prostate and gastrointestinal cancers.

Analysis of 10 genes

Screening for hereditary prostate cancer, colorectal cancer, and gastric cancer


Suitable for:

Men with a family history of related cancers

Middle-aged men or those with high-risk lifestyles or environmental exposures

Individuals seeking proactive genetic health screening


MEN - CARE is an important step in early cancer risk detection, enabling long-term prevention and medical follow-up.

PRE - CARE: Expanded screening for 15 hereditary cancers
PRE - CARE is an extended hereditary cancer testing package for individuals seeking more comprehensive risk assessment.

Analysis of mutations in 17 genes
Screening for 15 hereditary cancers, including: lung, stomach, breast, ovarian, colorectal, pancreatic, kidney, prostate, thyroid, skin, endometrial cancers, paraganglioma, retinoblastoma, pheochromocytoma, and multiple endocrine neoplasia


Suitable for:

Individuals with family histories of multiple cancer types
Those seeking expanded hereditary cancer screening
Individuals planning marriage or childbirth



PRO - CARE: Advanced hereditary cancer testing package
PRO - CARE provides a comprehensive overview of hereditary cancer risks.

Analysis of mutations in 133 genes

Screening for 30 hereditary cancers, including: lung, stomach, breast, ovarian, colorectal, pancreatic, kidney, prostate, thyroid, skin, endometrial, liver, bladder, head and neck, esophageal, biliary tract, small intestine, brain, bone, parathyroid cancers; acute leukemia (blood cancer); rhabdomyosarcoma; pituitary adenoma; neuroblastoma; neurofibroma; and multiple myeloma


Suitable for:

Individuals at high risk of cancer
Families with multiple affected members
Those requiring comprehensive genetic evaluation for long-term monitoring



DIAMOND - CARE: The most comprehensive genetic testing package
DIAMOND - CARE is the most advanced and comprehensive package at Eurofins GENTIS, combining hereditary cancer screening with inherited chronic disease testing.

Total analysis of 177 genes associated with 69 hereditary chronic diseases and cancers, including:



 10 genes – 9 common autosomal recessive disorders:
 Alpha Thalassemia, Beta Thalassemia, G6PD deficiency, Phenylketonuria (PKU), Galactose metabolism disorder, Citrin deficiency–related cholestasis, 5-Alpha Reductase deficiency–related male sex development disorder, Pompe disease, Wilson disease
 133 genes – Screening for 30 hereditary cancers (entire PRO - CARE panel)
 34 genes – 30 hereditary syndromes and chronic conditions:
 20 cardiovascular diseases, 5 connective tissue disorders, and 5 endocrine–metabolic disorders

DIAMOND - CARE is especially suitable for individuals seeking a comprehensive evaluation of hereditary health risks for themselves and their families.
With advanced gene sequencing technology, strict quality control processes, and a highly experienced team of experts, Eurofins GENTIS is committed to delivering accurate, reliable, and clinically valuable results.
Hereditary cancer testing is not just a test — it is a proactive step toward early prevention, appropriate monitoring, and personalized healthcare.
Contact Eurofins GENTIS via hotline 1800 2010 for detailed consultation and to choose the most suitable testing package for you and your family.

            [content_more] => 
            [meta_title] => Summary of 5 hereditary cancer testing packages at Eurofins GENTIS
            [meta_description] => Cancer is one of the leading causes of death worldwide. Numerous studies indicate that 5–10% of cancer cases are associated with hereditary factors, resulting from gene mutations that can be passed down from one generation to the next. Hereditary cancer t
            [meta_keyword] => GENTIS,genetic disorder
            [thumbnail_alt] => 
            [post_id] => 1408
            [category_id] => 14
        )

    [4] => stdClass Object
        (
            [id] => 1406
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => img_4684.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2026-02-06
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-02-06 08:41:18
            [updated_time] => 2026-02-07 09:25:41
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS's-year-end-party-2025-United-as-one-steadfast-forward
            [title] => Eurofins GENTIS's year end party 2025 - United as one, steadfast forward
            [description] => Eurofins GENTIS solemnly hosted the Year End Party 2025 with the theme “United as One, Steadfast Forward.” The event was not only an occasion to review and reflect on a year of development, but also a meaningful space for connection, where the entire Eurofins GENTIS family gathered, shared, and spread the spirit of unity and determination toward the future.
            [content] => 
Year End Party 2025 took place in an atmosphere that was both formal and warm, vibrant yet heartfelt, leaving many emotions and lasting impressions on every employee, partner, and expert in attendance.

Looking back at 2025 – A  year of effort and achievement
The year 2025 marked a period of strong growth for Eurofins GENTIS with many important milestones. The achievements were not only reflected in growth figures, but also in improvements in service quality, brand reputation, and the professional working spirit of the entire team.
The Year End Party was an opportunity for the Eurofins GENTIS collective to look back on that journey — a journey built on perseverance, responsibility, and unity from every individual. Each member, in different roles, contributed to a proud overall picture that reflects the company’s sustainable development.

Eurofins GENTIS highly appreciates and values the presence of our esteemed partners and experts at the Year End Party 2025. Their attendance was not only an honor, but also a testament to the strong, trustworthy, and long-term partnerships between Eurofins GENTIS and its collaborators.
The trust and support from our partners and experts have played a vital role in the successes Eurofins GENTIS achieved throughout 2025. The party was an occasion for all sides to reflect on the journey so far, while opening new expectations for deeper and more effective cooperation in the future.

One of the most memorable and emotional moments of the program was the group photo of Eurofins GENTIS employees together with partners and experts. In a space filled with joy and pride, every smile and every glance reflected unity, connection, and confidence in the road ahead.
The photo not only captured a moment, but also became a symbol of the message “United as One, Steadfast Forward” — when everyone shares the same goals, looks toward the future, and is ready to work together to build a stronger Eurofins GENTIS.

At the Year End Party 2025, Mr. Do Manh Ha – General Director of Eurofins GENTIS — delivered an important speech sharing the company’s outstanding achievements in 2025. These results clearly demonstrate the right strategies, the determination of the leadership team, and the tireless efforts of all employees.
In addition to reflecting on the past year, the General Director also affirmed the vision, goals, and development directions for 2026, with expectations to further improve service quality, expand cooperation, and strengthen Eurofins GENTIS’s position in its field of expertise. His sharing was not only strategic in orientation but also highly inspiring, motivating the entire team to enter the new year with greater confidence and determination.

A meaningful and significant part of the Year End Party 2025 was the ceremony honoring outstanding individuals and teams. These were the faces that made remarkable contributions, demonstrating responsibility, creativity, and continuous effort throughout the year.






Each name called was a story of dedication, a testament to wholehearted commitment and the aspiration to grow. The enthusiastic applause was not only well-deserved recognition but also a great source of encouragement, spreading positivity and promoting a culture of recognition and appreciation at Eurofins GENTIS.
After the formal moments, the program moved into the year-end banquet in a lively, cozy, and joyful atmosphere. New Year wishes and shared stories helped erase distances and brought members closer together.
Additionally, awards for outstanding activities and contributions were not only a form of recognition but also motivation for all employees to continue being creative, striving, and accompanying Eurofins GENTIS on its development journey ahead.







An indispensable part of the Year End Party 2025 was the exciting Lucky Draw. The suspenseful waiting moments and the bursts of cheers when attractive prizes found their winners made the atmosphere even more energetic.
More than just prizes, the Lucky Draw was an occasion for everyone to share joy, create memorable moments, and strengthen the bonds among members of the Eurofins GENTIS family.
Closing a memorable year, ready for a new journey
Year End Party 2025 – “United as One, Steadfast Forward” concluded in a joyful, warm, and emotional atmosphere. The year 2025 left many proud marks, serving as a strong foundation for Eurofins GENTIS to enter 2026 with greater confidence, ambition, and determination.

With a spirit of unity, solidarity, and continuous effort from the entire team, Eurofins GENTIS will continue moving forward together, reaching new heights and building a more sustainable and brilliant future in the years to come.
            [content_more] => 
            [meta_title] => Eurofins GENTIS's year end party 2025 - United as one, steadfast forward
            [meta_description] => Eurofins GENTIS solemnly hosted the Year End Party 2025 with the theme “United as One, Steadfast Forward.” The event was not only an occasion to review and reflect on a year of development, but also a meaningful space for connection, where the entire Euro
            [meta_keyword] => GENTIS,YEAR END PARTY
            [thumbnail_alt] => 
            [post_id] => 1406
            [category_id] => 14
        )

    [5] => stdClass Object
        (
            [id] => 1405
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => z7475342255361_6d2a37fa1d1528705dc55057db6a4222.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 0000-00-00
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-01-29 13:20:52
            [updated_time] => 2026-01-30 13:30:18
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-and-Phenikaa-hospital-strengthen-professional-exchange-on-preimplantation-genetic-testing
            [title] => Eurofins GENTIS and Phenikaa hospital strengthen professional exchange on preimplantation genetic testing
            [description] => In recent years, alongside in vitro fertilization (IVF), preimplantation genetic testing (PGT) solutions have increasingly been recognized as a key factor in improving success rates, minimizing risks, and working toward the goal of delivering healthy babies. Scientifically guided embryo selection plays a crucial role in helping clinicians and patients make safer and more effective decisions in each treatment cycle.
            [content] => 

Responding to the growing demand for the application of PGT solutions in assisted reproduction, Eurofins GENTIS recently collaborated with Phenikaa Hospital to organize a professional working session. The meeting focused on exchanging insights and updating advanced genetic testing solutions currently applied in reproductive medicine, including specialized technologies and services developed and implemented by Eurofins GENTIS.
Representing Eurofins GENTIS, Dr. Nguyen Quang Vinh (Laboratory Director) directly presented and reported on the professional content at the session. On the Phenikaa Hospital side, the meeting was attended by a team of physicians, specialists, and technicians in assisted reproduction, who engaged in in-depth discussions on the practical application of genetic testing in IVF treatment.

At the meeting, Dr. Vinh provided an overview of the PGT testing system currently implemented at Eurofins GENTIS, with a focus on PGT-A/SR—preimplantation genetic testing for aneuploidies and structural rearrangements. PGT-A/SR enables comprehensive analysis of all 24 chromosomes, detecting numerical and structural abnormalities, including aneuploidy, deletions, duplications, and mosaicism. The application of PGT-A/SR helps IVF clinicians select embryos with higher implantation potential, reduce the risk of early miscarriage, and increase embryo transfer success rates, particularly in advanced-age patients, those with repeated IVF failures, or a history of pregnancy loss. Data shared by Eurofins GENTIS showed that embryos with chromosomal abnormalities account for nearly half of all analyzed samples. This highlights the importance of preimplantation genetic testing, as many embryos with good morphology may still harbor underlying genetic abnormalities that can directly affect pregnancy outcomes if not screened early.
In addition to PGT-A/SR, PGT-M was another topic of particular interest to Phenikaa Hospital. This solution is designed for couples who carry genes associated with inherited diseases but wish to have healthy children free from these conditions. Eurofins GENTIS has currently implemented more than 100 PGT-M protocols for a wide range of conditions such as thalassemia, spinal muscular atrophy (SMA), hemophilia, and other rare genetic disorders, using advanced technologies including next-generation sequencing (NGS), STR, SNP analysis, and karyomapping. The integration of PGT-M with IVF helps prevent genetic diseases at the embryo stage, delivering long-term benefits for the health of future generations.
Within the framework of the session, Dr. Vinh also highlighted Eurofins GENTIS’s testing capacity and internationally standardized laboratory system, featuring the Illumina MiSeq NGS platform and specialized analysis software BlueFuse. Notably, the achievement of CAP accreditation for PGT testing serves as strong evidence of quality, reliability, and standardization across the entire genetic testing workflow at GENTIS.
Beyond introducing genetic testing services and modern laboratory infrastructure, Dr. Nguyen Quang Vinh also directly addressed professional questions from Phenikaa Hospital’s experts and physicians, helping clarify practical issues related to the application of genetic testing in assisted reproduction. Physicians at Phenikaa Hospital highly appreciated the professional insights, real-world data, and testing solutions provided by Eurofins GENTIS, considering them an important foundation for improving treatment outcomes and the quality of care for IVF patients.
The professional exchange between Eurofins GENTIS and Phenikaa Hospital not only held academic value but also opened up directions for sustainable collaboration in training, clinical consultation, and the implementation of advanced genetic testing solutions. Through close cooperation, both parties expect to contribute to improving IVF treatment effectiveness, reducing the psychological and financial burden on patients, and delivering meaningful value to the community in the journey toward fulfilling the dream of having healthy children.
            [content_more] => 
            [meta_title] => Eurofins GENTIS and Phenikaa hospital strengthen professional exchange on preimplantation genetic te
            [meta_description] => In recent years, alongside in vitro fertilization (IVF), preimplantation genetic testing (PGT) solutions have increasingly been recognized as a key factor in improving success rates, minimizing risks, and working toward the goal of delivering healthy babi
            [meta_keyword] => GENTIS,Phenikaa
            [thumbnail_alt] => 
            [post_id] => 1405
            [category_id] => 14
        )

    [6] => stdClass Object
        (
            [id] => 1404
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => rabbit_media-4214.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2026-01-23
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-01-23 10:43:46
            [updated_time] => 2026-01-30 13:27:57
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Trends-and-applications-of-AI-and-omics-data-in-genetic-testing-and-reproductive-genetic-counseling
            [title] => Trends and applications of AI and omics data in genetic testing and reproductive genetic counseling
            [description] => In recent years, artificial intelligence (AI) has emerged as one of the key driving forces behind the technological revolution across many fields, especially healthcare. From medical imaging diagnostics and chronic disease management to drug research and development, AI has demonstrated its pivotal role in improving treatment effectiveness and personalizing healthcare. In the field of genetics and assisted reproduction, the integration of AI, bioinformatics, and Omics data is expected to create major breakthroughs, significantly enhancing the quality of screening, diagnosis, and genetic counseling.
            [content] => 
AI and omics data – The foundation of precision medicine
 The rapid development of next-generation sequencing (NGS), mass spectrometry technologies, along with the increasing capacity for collecting and storing large-scale clinical data, has generated an enormous volume of information in medical genetics. Omics data—including genomics, transcriptomics, proteomics (proteins and post-translational modifications), metabolomics (metabolites and hormones), together with bioinformatics and AI—provide a comprehensive reflection of biological characteristics at the molecular level. However, analyzing and effectively exploiting these datasets poses a major challenge if relying solely on traditional methods.
Dr. Pham Dinh Minh (R&D Director, Eurofins GENTIS) presenting at the Symposium on Reproductive Genetics and PGT
With its machine learning capabilities and multidimensional data analysis, AI enables rapid and accurate processing of complex Omics datasets, thereby uncovering potential relationships among genetic factors, clinical data, and disease risks. In assisted reproduction, this opens up opportunities to improve embryo screening quality, predict implantation potential, and provide more scientific and personalized genetic risk counseling for couples.
Eurofins GENTIS pioneers the application of AI in reproductive genetics
 According to Dr. Pham Dinh Minh (R&D Director of Eurofins GENTIS) at the Symposium on Reproductive Genetics and PGT, in recent years Eurofins GENTIS has focused on developing information technology platforms and AI applications integrated with Omics data to support genetic screening, counseling, and management of hereditary diseases. These solutions not only provide professional support for hospitals and partners but also strengthen the connection between Eurofins GENTIS, clinicians, healthcare facilities, and patients, contributing to improved user experience and healthcare service quality.
In the field of genetic analysis, Eurofins GENTIS has been researching and developing various bioinformatics tools to support the application of AI in studying the molecular mechanisms of fertilization, embryo development, and factors affecting infertility and subfertility. These studies aim to improve the success rates of in vitro fertilization (IVF) and to personalize treatment for each patient in the future.
PGT-AI – A new approach to embryo selection
One of the greatest challenges in IVF today is how to increase pregnancy rates and the likelihood of delivering healthy babies after embryo transfer. According to Dr. Pham Dinh Minh, the embryo is the decisive factor determining the success of an IVF cycle. Selecting the best embryo not only affects implantation rates but also has long-term implications for the child’s future health.
In this context, the application of artificial intelligence in preimplantation genetic testing (PGT-AI) is considered a highly promising trend. PGT-AI goes beyond the assessment of chromosomal abnormalities in embryos and aims to select the “best embryo among good embryos” from a genetic perspective.

Eurofins GENTIS Is researching the application of AI to predict embryo transfer success


Currently, Eurofins GENTIS is conducting pilot studies on applying AI to predict the success potential of embryo transfer. By analyzing the genetic data of embryos in combination with maternal clinical factors, AI can help identify relationships between embryos and their compatibility with the uterine environment. This enables clinicians to make optimal embryo selection decisions, thereby improving implantation rates and overall IVF success.
By integrating maternal clinical data and expanding the analysis of embryonic genetic data within PGT-AI, the research team at Eurofins GENTIS is developing screening and predictive models to identify healthy embryos with high implantation potential. This is regarded as an important step toward personalized counseling and assisted reproductive treatment.
Applications of AI in NIPT and newborn screening
In addition to IVF and PGT-AI, AI is also being strongly applied by Eurofins GENTIS in the fields of prenatal and newborn screening. In non-invasive prenatal testing (NIPT), Eurofins GENTIS collaborates with the University of Engineering and Technology – Vietnam National University, Hanoi, to develop bioinformatics algorithms that expand the detection spectrum of genetic variants. As a result, the sensitivity, accuracy, and specificity of NIPT have been significantly improved, contributing to higher-quality fetal anomaly screening.
Eurofins GENTIS Is researching and applying AI and Information technology in newborn screening
For newborn screening, Eurofins GENTIS is developing AI-integrated software solutions to enhance the detection of complex metabolic disorders based on mass spectrometry data. From these datasets, algorithms are built to support rapid and accurate early prediction and diagnosis of genetic diseases related to metabolic disorders in newborns.
Notably, in the process of reporting results, Eurofins GENTIS has integrated information technology and AI to interpret testing data, helping clinicians and families more easily access disease-related information, understand risks, and determine appropriate treatment directions for infants.
The application of AI and Omics data in genetic testing and counseling is ushering in a new era for assisted reproduction and precision medicine. With ongoing research and real-world applications, Eurofins GENTIS demonstrates its pioneering role in bringing advanced technologies into reproductive healthcare services in Vietnam.
In the future, as datasets become more comprehensive and AI algorithms more refined, AI-based genetic solutions are expected to support clinicians in making more accurate decisions, optimizing treatment outcomes, creating opportunities for parenthood for many infertile couples, and contributing to sustainable improvements in population health.
            [content_more] => 
            [meta_title] => Trends and applications of AI and omics data in genetic testing and reproductive genetic counseling
            [meta_description] => In recent years, artificial intelligence (AI) has emerged as one of the key driving forces behind the technological revolution across many fields, especially healthcare. From medical imaging diagnostics and chronic disease management to drug research and 
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1404
            [category_id] => 14
        )

    [7] => stdClass Object
        (
            [id] => 1403
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => f28d3c7874e6fbb8a2f7.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2026-01-13
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-01-13 16:14:28
            [updated_time] => 2026-01-19 08:30:31
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Warning-of-fraudulent-impersonation-of-Eurofins-GENTIS-requesting-customers-to-transfer-money-for-early-delivery-of-test-results
            [title] => Warning of fraudulent impersonation of Eurofins GENTIS requesting customers to transfer money for early delivery of test results
            [description] => Dear Valued customers and partners,

            [content] => 
Recently, Eurofins GENTIS has received reports from several customers about unknown individuals calling by phone, impersonating company staff, and requesting payment of shipping fees for the delivery of test results (for NIPT tests and newborn screening tests), claiming that the results would be sent directly to the customers’ homes.

In response to this situation, Eurofins GENTIS would like to clearly affirm that the Company does not make phone calls requesting customers to transfer money via telephone or to personal accounts to pay any fees related to the delivery of test results. All service fees (if any) are publicly and transparently communicated at the time of registration and are implemented strictly in accordance with Eurofins GENTIS procedures. At the same time, we do not sell, provide, disclose, or allow the leakage of customers’ personal information in any form.
Currently, Eurofins GENTIS uses only one official customer service hotline: 1800 2010 to contact customers and notify them of test results. Any calls from other phone numbers requesting money transfers or personal information are not from Eurofins GENTIS.
In the context of rapid digital technology development, personal information may be collected from various sources and exploited for fraudulent activities, causing inconvenience and even serious impacts on customers’ rights and property. Therefore, Eurofins GENTIS kindly asks our partners and customers to remain vigilant, not to provide personal information, OTP codes, or bank account details, and not to transfer money without proper verification of the information.
Upon receiving any suspicious calls or unusual information related to test results, partners and customers are kindly requested to contact Eurofins GENTIS directly via the hotline 1800 2010 for timely verification and support.
Eurofins GENTIS sincerely thanks our valued partners and customers for their trust and companionship over the years, and kindly asks everyone to share this information with relatives and the community to help prevent unfortunate risks that may occur.
For further information, please contact:
EUROFINS GENTIS HANOI:
3rd Floor, V+ Shopping Center, 505 Minh Khai, Vinh Tuy Ward, Hanoi
EUROFINS GENTIS HO CHI MINH CITY:
8/24 Nguyen Dinh Khoi, Tan Son Nhat Ward, Ho Chi Minh City
Hotline: 1800 2010
Email: dichvu@gentis.com.vn
Sincerely,
            [content_more] => 
            [meta_title] => Warning of fraudulent impersonation of Eurofins GENTIS requesting customers to transfer money for ea
            [meta_description] => Dear Valued customers and partners,

            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1403
            [category_id] => 14
        )

)